Press releases

Month Year

Email alerts

Mar 17, 2021

Medtronic Receives Approval for U.S. Labeling of the Intellis™ Platform Showing Superior Back Pain Relief When Using DTM™ Spinal Cord Stimulation

Revised Commercial Labeling to Reflect Outcomes of a Randomized Controlled Trial Demonstrating Superiority of DTM™ Spinal Cord Stimulation (SCS) Compared to Conventional SCS for the Treatment of Chronic Intractable Back Pain

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis™...
- Photos 1
Mar 8, 2021

Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2021

The board of directors of Medtronic plc (NYSE: MDT) on Friday, March 5, 2021, approved the fiscal year 2021 fourth quarter cash dividend of $0.58 per ordinary share, representing a 7.4 percent...
Mar 4, 2021

Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation

Study Will Determine the Safety and Effectiveness of Pulsed Electrical Fields to Interrupt Irregular Heart Rhythms DUBLIN, March 4, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global...
Mar 2, 2021

New Analysis of REVERSE Trial Reveals Benefits of CRT for More Patients with Heart Failure

JACC: Clinical Electrophysiology: Findings Highlight Need to Better Classify Heart Failure Outcomes

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for...
Feb 23, 2021

Medtronic Reports Third Quarter Fiscal 2021 Financial Results

- Q3 Revenue of $7.8 Billion Increased 0.8% as Reported and Decreased 1.0% Organically - Q3 GAAP Diluted EPS of $0.94; Q3 Non-GAAP Diluted EPS of $1.29 DUBLIN, Feb. 23, 2021 /PRNewswire/ --...

Show per page